Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Change in Account Payables (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Change in Account Payables for 6 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 7.06% to $1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $977000.0, a 38.32% decrease, with the full-year FY2025 number at $977000.0, down 38.32% from a year prior.
  • Change in Account Payables was $1.7 million for Q4 2025 at Janux Therapeutics, up from -$168000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.6 million in Q3 2021 to a low of -$1.6 million in Q1 2025.
  • A 5-year average of $234150.0 and a median of $58000.0 in 2022 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: skyrocketed 5642.22% in 2021, then tumbled 326.17% in 2024.
  • Janux Therapeutics' Change in Account Payables stood at -$482000.0 in 2021, then skyrocketed by 146.27% to $223000.0 in 2022, then skyrocketed by 46.64% to $327000.0 in 2023, then surged by 376.76% to $1.6 million in 2024, then increased by 7.06% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Change in Account Payables are $1.7 million (Q4 2025), -$168000.0 (Q3 2025), and $1.1 million (Q2 2025).